|
| |
Rigel PharmaceuticalsRigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases.
Our goal is to file one new investigational new drug (IND) application in a significant indication each year. We have achieved this goal since 2002.
Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.
Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates.
We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as oncology.
R788 is our lead product candidate. We initiated Phase 2 efficacy studies in rheumatoid arthritis (RA) in 2H'06 and in immune thrombocytopenic purpura (ITP) in 1H'07. We expect results for these two studies in 2007. Rigel also initiated a Phase 2 study in lymphoma in 1H'07.
| Contact Details: |
| 1180 Veterans Boulevard |
| South San Francisco |
| CA |
| 94080 |
| United States of America |
| Tel: | 650.624.1100 |
| Fax: | 650 624 1101 |
| Email: | communications@rigel.com |
| WWW: | www.rigel.com/
|
|
Loading...
|
Recent Publications by Rigel Pharmaceuticals: |  |
Discovery and development of an aurora kinase inhibitor clinical candidate using an image-based assay for measuring proliferation, apoptosis, and DNA content.
Measurement of antiproliferative capacity of a compound is central to... | 12th August, 2009
| Rigel Pharmaceuticals, Inc., South San Francisco, California, USA.
| Assay Drug Dev Technol. 2009 Apr;7(2):180-90.
DOI Direct Link |
JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
JAK3, a member of the Janus kinase family, is predominantly expressed in... | 7th August, 2009
| Rigel Pharmaceuticals, Inc, South San Francisco, CA 94080, USA.
| J Immunol. 2009 Aug 1;183(3):2183-92. Epub 2009 Jul 13.
DOI Direct Link |
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.
PURPOSE: Aurora kinases play a key role in mitotic progression.... | 18th July, 2009
| Rigel Pharmaceuticals Inc., 1180 Veterans Boulevard, South San Francisco,
| J Cancer Res Clin Oncol. 2009 Jul 17.
DOI Direct Link |
IRS-2 and its involvement in diabetes and aging.
Insulin receptor substrate 2 (IRS-2) is a key molecule in insulin... | 24th June, 2009
| Rigel Pharmaceuticals, Inc., South San Francisco, California 94080, USA.
| Vitam Horm. 2009;80:389-407.
DOI Direct Link |
Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing.
BACKGROUND: Urogenital abnormalities are among the most common of all... | 15th April, 2009
| Rigel Pharmaceuticals, Inc., 1180 Veterans Blvd., South San Francisco, CA
| Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6.
DOI Direct Link |
→View more Rigel Pharmaceuticals research publications. |
Press Releases on Rigel Pharmaceuticals:
|
 |
| Rigel Announces Third Quarter 2009 Financial Results |
3rd November, 2009 |
Rigel Pharmaceuticals, Inc. |
SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2009
|
| Rigel Announces Presentations at Two Investor Conferences |
28th October, 2009 |
Rigel Pharmaceuticals, Inc. |
SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R.
|
| Rigel to Webcast Analyst Briefing on October 20, 2009 |
16th October, 2009 |
Rigel Pharmaceuticals, Inc. |
SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will webcast its analyst briefing on October 20, 2009 from 4:00-5:00pm
|
| Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors |
9th July, 2009 |
Poniard Pharmaceuticals, Inc. |
SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the
|
| Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial |
9th July, 2009 |
Rigel Pharmaceuticals, Inc. |
SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R788 (fostamatinib disodium) produced significant clinical improvement in
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 472 times since April 2007, the link to the organisation's website has been followed 67 times Recent Search Terms used to find this page: communications rigel | rigel reproductive toxicity R788 | rigel pharmaceutical logo | rigel june 2009 | R706 rigel | rigel pharmaceuticals 2009 | . Search for more companies in South San Francisco Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Rigel Pharmaceuticals |
